Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-1.50
EPS est.
$-1.63
EPS surprise
+8.20%
1-day move
+3.20%
Cytokinetics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 3.2%. However, there was no revenue reported or guidance provided, leaving investors with limited insights into future performance. The market's response suggests some optimism based on the EPS surprise.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.50 | N/A | +8.20% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Cytokinetics, Incorporated (CYTK) is a biotechnology company focused on developing treatments for serious diseases related to muscle function. With a market cap of $10 billion, it plays a significant role in the health care sector, particularly in addressing conditions like heart failure and muscle-related disorders.
Last quarter
In Q1-2026, Cytokinetics reported an EPS of -$1.67, matching analyst expectations with a slight surprise. The stock reacted positively, gaining 16.71% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-5.68%
Avg 1-day reaction
+2.72%
Overall, expectations for Cytokinetics are mixed as the company has shown volatility in past earnings reports. Investors are particularly interested in any updates regarding clinical trials and revenue growth.
Bull case
If Cytokinetics can demonstrate significant progress in its clinical trials and show improved revenue, it could lead to a strong positive reaction from the market.
Bear case
Conversely, if the company fails to meet expectations on trial results or shows continued losses, it could lead to a negative market reaction.
The print will turn on these.
Q1
What are the latest results from ongoing clinical trials?
The outcomes of these trials are crucial for the company's future product pipeline and can significantly influence investor sentiment.
Q2
What is the company's strategy for revenue growth moving forward?
Understanding the revenue growth strategy will provide insights into how Cytokinetics plans to achieve financial stability and profitability.
Est. EPS
$6.10
Est. Rev
$5.0B
Impl. Move
±5.3%
Why consensus could be wrong
The Street may be overly cautious about Cytokinetics' clinical trial outcomes, underestimating the potential for positive results that could drive significant revenue growth.
Supporting evidence
The company has a history of surprising investors positively despite recent losses.
Options pricing suggests a higher expected move than historical averages, indicating potential for a larger reaction.
Past performance shows that even slight beats can lead to substantial stock gains.
Key risk
If clinical trial results exceed expectations, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The market is weighing the potential for growth against the risks of ongoing losses and trial uncertainties.
Bull confirmed if
Demonstrating a clear path to profitability with revenue growth exceeding expectations.
Bear confirmed if
Failing to provide positive updates on clinical trials or showing continued losses.
What the market is pricing for the move.
Implied Move
±19.61%
Historical Avg
±4.7%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±19.6% while CYTK has averaged ±4.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
60.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$705,780.00
11,000 sh
2 insiders
Net
$705,780.00
Net selling
Most Active Insiders· 2 open-market trades
$490,950.00
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
125.94%
of float
Insider
0.64%
of float
Holders
657
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
20,094,362 sh · $1.2B
16.15%
21.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cytokinetics beats expectations, history suggests the stock could rise by an average of 5.17%, confirming a bullish outlook.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity.
Miss
If the company misses expectations, history indicates a potential decline of around 5.17%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
$214,830.00
Net selling
Recent Transactions
Sep 28, 2026 · @ $65.46
7,500 sh
$490,950.00
Oct 6, 2026 · @ $61.38
3,500 sh
$214,830.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
T. Rowe Price Investment Management, Inc.
18,718,498 sh · $1.1B
15.04%
6.8%
Wellington Management Group, LLP
6,931,770 sh · $423.7M
5.57%
-13.5%
Vanguard Portfolio Management LLC
6,711,799 sh · $410.2M
5.39%
14.9%
State Street Corporation
6,494,233 sh · $396.9M
5.22%
13.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jun 30, 2026 · disclosed Jul 2, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.